A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C]-Acoziborole in Healthy Male Subjects After Oral Dosing

Acoziborole (Figure 1), an oxaborole-6 carboxamide, is being developed as an oral single dose treatment for Human African trypanosomiasis (also called "sleeping sickness"). As part of the overall development programme, the mass balance, pharmacokinetics, metabolism and excretion of acoziborole were studied in an open-label, phase 1 study. This poster will describe the mass balance and clinical safety assessments from the human ADME study.